Nina Shah, MD
Internal Medicine · San Francisco, CANPI 1063692614
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $156,220 of the $197,017 with a category attached, or 79.3%. 22 manufacturers reported payments, led by Sanofi at 26.6% of the total. Reporting peaked in 2021 at $72,984 and has fallen 99.8% since, to $160 in 2024. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $1713.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$52K
- GSK$42K
- Karyopharm Therapeutics Inc.$25K
- AstraZeneca$23K
- Pfizer$11K
- AbbVie$10K
- plus $33K from 16 others
Across 123 payments — averaging $41,963 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$3.4M
- Janssen Research & Development, LLC$1.6M
- AbbVie$145K
- Genentech, Inc.$36K
- Amgen$4K
What the payments were for
- Consulting fees$156,22079%
- Speaking & faculty fees$23,82112%
- Grants$1030%
- Travel & lodging$6,2903%
- Food & beverage$2,6471%
- Education$7,9374%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 25 | $52,436 |
| GSK | 24 | $42,461 |
| Karyopharm Therapeutics Inc. | 12 | $24,741 |
| AstraZeneca | 2 | $23,290 |
| Pfizer | 7 | $11,063 |
| AbbVie | 5 | $10,271 |
| CSL Behring | 1 | $6,482 |
| Amgen | 5 | $5,124 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,525 |
| Gilead | 3 | $4,403 |
| Genentech, Inc. | 4 | $4,003 |
| Merck | 1 | $3,355 |
| Epizyme, Inc. | 1 | $1,500 |
| Bristol Myers Squibb | 7 | $1,290 |
| Janssen Global Services, LLC | 1 | $620 |
| Menarini Silicon Biosystems, Inc. | 1 | $500 |
| Seagen Inc. | 4 | $350 |
| Johnson & Johnson | 4 | $273 |
| Jazz Pharmaceuticals Inc. | 1 | $149 |
| Vifor Pharma, Inc. | 1 | $82 |
| Daiichi Sankyo Inc. | 1 | $62 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$197,017 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 11 | $208 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Francisco
- Fred CohenSan Francisco$929K
- John TeerlinkSan Francisco$819K
- Mark SmithSan Francisco$535K
- Lisa CapaldiniSan Francisco$434K
- Maria Dall'eraSan Francisco$417K
- Kenneth ColleySan Francisco$397K
- Louis CubbaSan Francisco$351K
- Daniel ButlerSan Francisco$347K
- Laurence CorashSan Francisco$336K
- Felicia StermanSan Francisco$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.